hMad4, c-Myc endogenous inhibitor, induces a replicative senescence-like state when overexpressed in human fibroblasts

Journal of Cellular Biochemistry

Volumn 89, Issue 3, 2003, Pages 576-588

  Marcotte, Richard ^a   Qian, Jing Fang ^b   Chen, James ^a   Wang, Eugenia ^b  

^a MCGILL UNIVERSITY   (Canada)

^b University of Louisville School of Medicine   (United States)

Author keywords

c Myc; hMad4; Senescence

Indexed keywords

BETA GALACTOSIDASE; CHLORAMPHENICOL ACETYLTRANSFERASE; MAX PROTEIN; MYC PROTEIN; PROTEIN HMAD4; PROTEIN MAD1; PROTEIN MAD4; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; E BOX ELEMENT; FIBROBLAST; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR CLONING; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE; SENESCENCE; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION; TRANSACTIVATION; WESTERN BLOTTING;

NON-PROGRAMMATIC;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL AGING; CELL DIVISION; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; FIBROBLASTS; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SMAD4 PROTEIN; TRANS-ACTIVATORS;

FELIS CATUS;

EID: 0038360762     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10517     Document Type: Article

References (54)

1. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. 1993a. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72:233-245.
2. Amati B, Littlewood TD, Evan GI, Land H. 1993b. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. Embo J 12:5083-5087.
3. Ayer DE, Eisenman RN. 1993. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/ macrophage differentiation. Genes Dev 7:2110-2119.
4. Ayer DE, Kretzner L, Eisenman RN. 1993. Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72:211-222.
5. Ayer DE, Lawrence QA, Eisenman RN. 1995. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776.
6. Baxendale S, MacDonald ME, Mott R, Francis F, Lin C, Kirby SF, James M, Zehetner G, Hummerich H, Valdes J, et al. 1993. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nat Genet 4:181-186.
7. Bello-Fernandez C, Packham G, Cleveland JL. 1993. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 90:7804-7808.
8. Berberich S, Hyde-DeRuyscher N, Espenshade P, Cole M. 1992. Max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors. Oncogene 7:775-779.
9. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. 1990. Sequence-specific DNA binding by the c-Myc protein. Science 250:1149-1151.
10. Blackwood EM, Eisenman RN. 1991. Max: A helix-loophelix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211-1217.
11. Blackwood EM, Luscher B, Eisenman RN. 1992. Myc and Max associate in vivo. Genes Dev 6:71-80.
12. Cerni C, Bousset K, Seelos C, Burkhardt H, Henriksson M, Luscher B. 1995. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. Oncogene 11:587-596.
13. Chen Q, Ames BN. 1994. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 91:4130-4134.
14. Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD. 1995. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling, and the malignant phenotype of human brain tumour cells. Nat Med 1:638-643.
15. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR. 2000. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97:3260-3265.
16. Cultraro CM, Bino T, Segal S. 1997. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation. Mol Cell Biol 17:2353-2359.
17. Dang CV. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11.
18. de Alboran IM, O'Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. 2001. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity 14: 45-55.
19. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92:9363-9367.
20. Facchini LM, Penn LZ. 1998. The molecular role of Myc in growth and transformation: Recent discoveries lead to new insights. Faseb J 12:633-651.
21. Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN. 1998. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. Embo J 17:774-785.
22. Galipeau J, Li H, Paquin A, Sicilia F, Karpati G, Nalbantoglu J. 1999. Vesicular stomatitis virus G pseudo-typed retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer. Cancer Res 59: 2384-2394.
23. Gehring S, Rottmann S, Menkel AR, Mertsching J, Krippner-Heidenreich A, Luscher B. 2000. Inhibition of proliferation and apoptosis by the transcriptional repressor Mad1. Repression of Fas-induced caspase-8 activation. J Biol Chem 275:10413-10420.
24. Goldstein S, Moerman EJ, Fujii S, Sobel BE. 1994. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J Cell Physiol 161:571-579.
25. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, Liu ET. 2000. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60:5922-5928.
26. Hann SR, Thompson CB, Eisenman RN. 1985. c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature 314:366-369.
27. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. 1997. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89:341-347.
28. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN. 1995. Mad3 and Mad4: Novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. Embo J 14:5646-5659.
29. Kato GJ, Barrett J, Villa-Garcia M, Dang CV. 1990. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10:5914-5920.
30. Koskinen PJ, Ayer DE, Eisenman RN. 1995. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions. Cell Growth Differ 6:623-629.
31. Kozak M. 1987. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15: 8125-8148.
32. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349-356.
33. Lahoz EG, Xu L, Schreiber-Agus N, DePinho RA. 1994. Suppression of Myc, but not Ela, transformation activity by Max-associated proteins, Mad, and Mxi1. Proc Natl Acad Sci USA 91:5503-5507.
34. Luscher B, Eisenman RN. 1990. New light on Myc and Myb. Part I. Myc. Genes Dev 4:2025-2035.
35. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. 1997. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8:1039-1048.
36. Michishita E, Nakabayashi K, Ogino H, Suzuki T, Fujii M, Ayusawa D. 1998. DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts. Biochem Biophys Res Commun 253:667-671.
37. Nesbit CE, Tersak JM, Prochownik EV. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
38. Nesbit CE, Tersak JM, Grove LE, Drzal A, Choi H, Prochownik EV. 2000. Genetic dissection of c-myc apoptotic pathways. Oncogene 19:3200-3212.
39. O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman JA, Schwab R, Alland L, Thomson C, Ronning DR, Sacchettini JC, Meltzer P, DePinho RA. 2000. Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet 24: 113-119.
40. Ogryzko W, Hirai TH, Russanova VR, Barbie DA, Howard BH. 1996. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol 16:5210-5218.
41. Prendergast GC. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18:2967-2987.
42. Queva C, Hurlin PJ, Foley KP, Eisenman RN. 1998. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 16:967-977.
43. Queva C, McArthur GA, Iritani BM, Eisenman RN. 2001. Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis. Mol Cell Biol 21: 703-712.
44. Rabbitts PH, Watson JV, Lamond A, Forster A, Stinson MA, Evan G, Fischer W, Atherton E, Sheppard R, Rabbitts TH. 1985. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. Embo J 4:2009-2015.
45. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA. 1995. An amino-terminal domain of Mxi mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80:777-786.
46. Schreiber-Agus N, Meng Y, Hoang T, Hou H, Jr., Chen K, Greenberg R, Cordon-Cardo C, Lee HW, DePinho RA. 1998. Role of Mxil in ageing organ systems and the regulation of normal and neoplastic growth. Nature 393: 483-487.
47. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, Eick D. 2001. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 29:397-406.
48. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602.
49. Sommer A, Bousset K, Kremmer E, Austen M, Luscher B. 1998. Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/ Mad network of transcriptional regulators. J Biol Chem 273:6632-6642.
50. Sugrue MM, Shin DY, Lee SW, Aaronson SA. 1997. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 94:9648-9653.
51. Uhrbom L, Nister M, Westermark B. 1997. Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15:505-514.
52. Wang E. 1985a. Rapid disappearance of statin, a nonproliferating and senescent cell-specific protein, upon reentering the process of cell cycling. J Cell Biol 101: 1695-1701.
53. Wang E. 1985b. Disappearance of statin, a protein marker for non-proliferating and senescent cells, following serum-stimulated cell cycle entry. Exp Cell Res 167: 135-143.
54. Zervos AS, Gyuris J, Brent R. 1993. Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72:223-232.